Abstract
The continuum model of psychosis posits that psychotic symptoms are distributed throughout the population, with diagnosable clinical disorder existing at a certain point along this continuum. The total continuum is made up mainly of non-clinical cases with clinical cases of psychosis representing only a small proportion of the total extended psychosis phenotype. This paper is a narrative review of studies of psychotic experiences in the general population. The evidence indicates reasonably high prevalence rates of psychotic experiences in the general population, substantially higher than the prevalence of psychotic disorders, and that they are associated with increased risk of future onset of diagnosable disorder, particularly when the experiences are persistent. Psychotic experiences in the general population share an extensive range of risk factors with schizophrenia and therefore provide a useful phenotype in which to study the aetiology of clinical psychosis. Some types of psychotic experiences, such as paranoid ideas, bizarre thinking and perceptual abnormalities, may indicate a greater level of risk for psychotic disorder than other psychotic experiences, such as magical thinking. There is a need for research that further explores the interplay between psychotic experiences and other risk factors (including psychological, environmental, neurocognitive and genetic factors) in the evolution of psychotic disorder, the types of psychotic experiences that are most associated with risk for clinical disorder, the specificity of risk associated with psychotic experiences, and the possible adaptive advantages of these experiences.
Keywords: Psychosis, schizophrenia, risk, continuum, phenotype, schizotypy, adolescents, hallucinations, depression, PLEs
Current Pharmaceutical Design
Title: Can We Detect Psychotic-like Experiences in the General Population?
Volume: 18 Issue: 4
Author(s): B. Nelson, P. Fusar-Poli and A. R. Yung
Affiliation:
Keywords: Psychosis, schizophrenia, risk, continuum, phenotype, schizotypy, adolescents, hallucinations, depression, PLEs
Abstract: The continuum model of psychosis posits that psychotic symptoms are distributed throughout the population, with diagnosable clinical disorder existing at a certain point along this continuum. The total continuum is made up mainly of non-clinical cases with clinical cases of psychosis representing only a small proportion of the total extended psychosis phenotype. This paper is a narrative review of studies of psychotic experiences in the general population. The evidence indicates reasonably high prevalence rates of psychotic experiences in the general population, substantially higher than the prevalence of psychotic disorders, and that they are associated with increased risk of future onset of diagnosable disorder, particularly when the experiences are persistent. Psychotic experiences in the general population share an extensive range of risk factors with schizophrenia and therefore provide a useful phenotype in which to study the aetiology of clinical psychosis. Some types of psychotic experiences, such as paranoid ideas, bizarre thinking and perceptual abnormalities, may indicate a greater level of risk for psychotic disorder than other psychotic experiences, such as magical thinking. There is a need for research that further explores the interplay between psychotic experiences and other risk factors (including psychological, environmental, neurocognitive and genetic factors) in the evolution of psychotic disorder, the types of psychotic experiences that are most associated with risk for clinical disorder, the specificity of risk associated with psychotic experiences, and the possible adaptive advantages of these experiences.
Export Options
About this article
Cite this article as:
Nelson B., Fusar-Poli P. and R. Yung A., Can We Detect Psychotic-like Experiences in the General Population?, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316136
DOI https://dx.doi.org/10.2174/138161212799316136 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression and Purification of Uniformly 15N-Labeled Amyloid β Peptide 1-40 in Escherichia coli
Protein & Peptide Letters Overview: Translating Hsp90 Biology into Hsp90 Drugs
Current Cancer Drug Targets Nitric Oxide Induced Damage and Preventive Effect of Curcumin and Quercetin on Buffalo Brain Cystatin
Current Proteomics Body Fluids-Derived Exosomes: Paving the Novel Road to Lung Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Flavonoids in the Treatment of Alzheimer’s and Other Neurodegenerative Diseases
Current Medicinal Chemistry Detection of Biothiols Using Some Novel Chemosensors: An Overview
Mini-Reviews in Organic Chemistry Antipsychotic Medication Adherence and Satisfaction Among Palestinian People with Schizophrenia
Current Clinical Pharmacology Vascular Stiffness: Measurements, Mechanisms and Implications
Current Vascular Pharmacology Glycemic Control is Related to Cognitive Dysfunction in Elderly People with Type 2 Diabetes Mellitus in a Rural Chinese Population
Current Alzheimer Research Ameliorative Effects of GW1929, a Nonthiazolidinedione PPARγ Agonist,on Inflammation and Apoptosis in Focal Cerebral Ischemic-Reperfusion Injury
Current Neurovascular Research Anhedonia and Increased Stress Sensitivity: Two Promising Endophenotypes for Major Depression
Current Psychiatry Reviews Peptides as Modulators of α-Synuclein Aggregation
Protein & Peptide Letters The Latent Structure of Mental Disorders: A Taxometric Update on the Categorical vs Dimensional Debate
Current Psychiatry Reviews From Cerebrospinal Fluid Pulsation to Noninvasive Intracranial Compliance and Pressure Measured by MRI Flow Studies
Current Medical Imaging Morphine Stimulates Vascular Endothelial Growth Factor-Like Signaling in Mouse Retinal Endothelial Cells
Current Neurovascular Research Molecular Design of Bioconjugated Cell Adhesion Peptide with a Water-Soluble Polymeric Modifier for Enhancement of Antimetastatic Effect
Current Drug Targets Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System
Current Neuropharmacology Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets Sepsis in the Central Nervous System and Antioxidant Strategies with Nacetylcysteine, Vitamins and Statins
Current Neurovascular Research Treatment of Obesity: Should We Target the Individual or Society?
Current Pharmaceutical Design